Hepatitis A Seroprevalence in Different Age Groups in a Region With Low and Moderate Socioeconomic Level in Izmir Province: Results of A Fieldwork

WOS: 000511173500016Objective: the aim of this study was to investigate hepatitis A seroprevalence by means of a prospective fieldwork in different age groups in a region with low and moderate socioeconomic and cultural level in Izmir. Methods: This study was conducted between September 2015 and September 2016. After the consent forms of the volunteers (from parents for children) were obtained, 6 ml blood samples were taken from individuals and anti-HAV IgG was determined by enzyme immunoassay method. A questionnaire including the indicators of the welfare level used in the World Health Survey was applied to determine the level of welfare of individuals aged 16 years and older. All data were recorded in IBM SPSS Statistics for Windows, Version 21.0 (IBM Corp., Armonk, NY, USA) computer program for analysis. Results: 1336 individuals participated in the study and 989 (74%) of the participants had anti-HAV IgG seropositivity. the rate of seropositivity was 87.5% in the = 20 age group, and 95.8% in >= 55 age group. 851 people completed the questionnaire about socioeconomic status. Socioeconomic level of those individuals was low in 32.9%, was moderate in 51.8%, and was high in 15.3%. Hepatitis A seropositivity was found in 81.8% of the individuals who completed the questionnaire. A statistically significant correlation was found between socioeconomic status and hepatitis A seropositivity (p=0.005). Conclusions: in our study, the rate of seropositivity was found to be higher in children aged = 5 years, adolescents and young adults. We interpreted this situation as a reflection of the epidemiological switch. It was thought that this fact should be taken into consideration in vaccination practices

IDENTIFICATION OF CANDIDA SPECIES ISOLATED FROM CLINICAL SAMPLES AND INVESTIGATING ANTIFUNGAL SUSCEPTIBILITY IN TURKEY

WOS: 000344634100002Objectives: The purpose of this study is identify typology of candida species from patients' samples, and determine their in-vitro antifungal susceptibility. Materials and methods: In this study, Candida species isolated from patients who applied to our laboratory between 20092010 were included in order to identify the types of Candida and to carry out their antifungal sensitivity. The Candida species were typed using germ tube test, corn meal Tween-80 and BBL CHROMagar medium, and API ID32C yeast identification system. Antifungal drugs' susceptibility of Candida species for amphotericin B, fluconazole, itraconazole, and voriconazole were conducted through microdilution system. Results: Of the 97 Candida species, 58.76% were identified as Candida albicans, other identified types were as follows: C. parapsilosis (13.4%), C. glabrata (11.3%), C. tropicalis (5.15%) respectively. Antifungal drugs sensitivity tests results revealed 1.03% resistance to fluconazole and 4.12% to itracanazole, whereas no resistance was found to amphotericin B and voriconazole. Conclusion: Target population for Candida has gradually been expanding. Therefore, it may be suggested that determining the type of pathogen and running its susceptibility tests are significant factors that will enhance the success of the treatment before empirical treatment against Candida infections is initiated

Results of a multinational study suggest the need for rapid diagnosis and early antiviral treatment at the onset of herpetic meningoencephalitis

Data in the literature regarding the factors that predict unfavorable outcomes in adult herpetic meningoencephalitis (HME) cases are scarce. We conducted a multicenter study in order to provide insights into the predictors of HME outcomes, with special emphasis on the use and timing of antiviral treatment. Samples from 501 patients with molecular confirmation from cerebrospinal fluid were included from 35 referral centers in 10 countries. Four hundred thirty-eight patients were found to be eligible for the analysis. Overall, 232 (52.9%) patients experienced unfavorable outcomes, 44 died, and 188 survived, with sequelae. Age (odds ratio [OR], 1.04; 95% confidence interval [CI], 1.02 to 1.05), Glasgow Coma Scale score (OR, 0.84; 95% CI, 0.77 to 0.93), and symptomatic periods of 2 to 7 days (OR, 1.80; 95% CI, 1.16 to 2.79) and >7 days (OR, 3.75; 95% CI, 1.72 to 8.15) until the commencement of treatment predicted unfavorable outcomes. The outcome in HME patients is related to a combination of therapeutic and host factors. This study suggests that rapid diagnosis and early administration of antiviral treatment in HME patients are keys to a favorable outcome

Managing Atypical and Typical herpetic central nervous system infections: results of A Multinational study

International audienceThere have been many studies pertaining to the management of herpetic meningoencephalitis (HME), but the majority of them have focused on virologically unconfirmed cases or included only small sample sizes. We have conducted a multicentre study aimed at providing management strategies for HME. Overall, 501 adult patients with PCR-proven HME were included retrospectively from 35 referral centres in 10 countries; 496 patients were found to be eligible for the analysis. Cerebrospinal fluid (CSF) analysis using a PCR assay yielded herpes simplex virus (HSV)-1 DNA in 351 patients (70.8%), HSV-2 DNA in 83 patients (16.7%) and undefined HSV-DNA type in 62 patients (12.5%). A total of 379 patients (76.4%) had at least one of the specified characteristics of encephalitis, and we placed these patients into the encephalitis presentation group. The remaining 117 patients (23.6%) had none of these findings, and these patients were placed in the non-encephalitis presentation group. Abnormalities suggestive of encephalitis were detected in magnetic resonance imaging (MRI) in 83.9% of the patients and in electroencephalography (EEG) in 91.0% of patients in the encephalitis presentation group. In the non-encephalitis presentation group, MRI and EEG data were suggestive of encephalitis in 33.3% and 61.9% of patients, respectively. However, the concomitant use of MRI and EEG indicated encephalitis in 96.3% and 87.5% of the cases with and without encephalitic clinical presentation, respectively. CSF HSV-PCR, EEG and MRI data should be collected for all patients with a central nervous system infection considering the subtle nature of HM

Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey

Background: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors

Quality of life and related factors among chronic hepatitis B-infected patients: a multi-center study, Turkey

balkan, ilker inanc/0000-0002-8977-5931; Altindis, Mustafa/0000-0003-0411-9669; Sahin, Ahmet Ziyaettin/0000-0003-1060-6746; atilla, aynur/0000-0001-8027-1991WOS: 000386954300001PubMed: 27809934Background: The aim of this study was to assess health-related quality of life (HRQOL) among chronic hepatitis B (CHB) patients in Turkey and to study related factors. Methods: This multicenter study was carried out between January 01 and April 15, 2015 in Turkey in 57 centers. Adults were enrolled and studied in three groups. Group 1: Inactive HBsAg carriers, Group 2: CHB patients receiving antiviral therapy, Group 3: CHB patients who were neither receiving antiviral therapy nor were inactive HBsAg carriers. Study data was collected by face-to-face interviews using a standardized questionnaire, Short Form-36 (SF-36) and Hepatitis B Quality of Life (HBQOL). Values equivalent to p < 0.05 in analyses were accepted as statistically significant. Results: Four thousand two hundred fifty-seven patients with CHB were included in the study. Two thousand five hundred fifty-nine (60.1 %) of the patients were males. Groups 1, 2 and 3, consisted of 1529 (35.9 %), 1721 (40.4 %) and 1007 (23.7 %) patients, respectively. The highest value of HRQOL was found in inactive HBsAg carriers. We found that total HBQOL score increased when antiviral treatment was used. However, HRQOL of CHB patients varied according to their socio-demographic properties. Regarding total HBQOL score, a higher significant level of HRQOL was determined in inactive HBV patients when matched controls with the associated factors were provided. Conclusions: The HRQOL score of CHB patients was higher than expected and it can be worsen when the disease becomes active. Use of an antiviral therapy can contribute to increasing HRQOL of patients